Page last updated: 2024-09-05

erlotinib and bicalutamide

erlotinib has been researched along with bicalutamide in 2 studies

Compound Research Comparison

Studies
(erlotinib)
Trials
(erlotinib)
Recent Studies (post-2010)
(erlotinib)
Studies
(bicalutamide)
Trials
(bicalutamide)
Recent Studies (post-2010) (bicalutamide)
22101801,313212541

Protein Interaction Comparison

ProteinTaxonomyerlotinib (IC50)bicalutamide (IC50)
Progesterone receptorOryctolagus cuniculus (rabbit)5.6
Progesterone receptorHomo sapiens (human)1.819
Androgen receptorHomo sapiens (human)0.404
Androgen receptorRattus norvegicus (Norway rat)0.7168
Androgen receptorMus musculus (house mouse)1.835
Testosterone 17-beta-dehydrogenase 3Homo sapiens (human)0.12
Progesterone receptorRattus norvegicus (Norway rat)0.89

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for erlotinib and bicalutamide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

1 other study(ies) available for erlotinib and bicalutamide

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013